EventsThe 2nd International Electronic Conference on Clinical Medicine
Published
This submission belongs to the session S1. Cardiology of the event The 2nd International Electronic Conference on Clinical Medicine
Published date
11 Nov, 2024
Academic Editor
author-avatarEmmanuel Andrès
Citation
Yongting Luo, The activator protein-1 complex governs a vascular degenerative transcriptional programme in smooth muscle cells to trigger aortic dissection and rupture, in Proceedings of The 2nd International Electronic Conference on Clinical Medicine, 13 November–15 November 2024, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

The activator protein-1 complex governs a vascular degenerative transcriptional programme in smooth muscle cells to trigger aortic dissection and rupture

image
1. Department of Nutrition and Health, China Agricultural University, China, China
Abstract

Background and aims: Stanford type A aortic dissection (AD) is a degenerative aortic remodelling disease marked by exceedingly high mortality without effective pharmacologic therapies. Smooth muscle cells (SMCs) lining tunica media adopt a range of states, and their transformation from contractile to synthetic phenotypes fundamentally triggers AD. However, the underlying pathomechanisms governing this population shift, and subsequent AD, particularly at distinct disease temporal stages, remain elusive.

Methods: Ascending aortas from nine patients undergoing ascending aorta replacement and five individuals undergoing heart transplantation were subjected to single-cell RNA sequencing. The pathogenic targets governing the phenotypic switch of SMCs were identified by trajectory inference, functional scoring, single-cell regulatory network inference, and clustering, regulon, and interactome analyses, and confirmed using human ascending aortas, primary SMCs, and a β-aminopropionitrile monofumarate-induced AD model.

Results: The transcriptional profiles of 93 397 cells revealed a dynamic temporal-specific phenotypic transition and marked elevation of the activator protein-1 (AP-1) complex, actively enabling synthetic SMC expansion. Mechanistically, tumour necrosis factor signalling enhanced AP-1 transcriptional activity by dampening mitochondrial oxidative phosphorylation (OXPHOS). Targeting this axis with the OXPHOS enhancer coenzyme Q10 or AP-1-specific inhibitor T-5224 impedes phenotypic transition and aortic degeneration while improving survival by 42.88% (58.3%-83.3% for coenzyme Q10 treatment), 150.15% (33.3%-83.3% for 2-week T-5224), and 175.38% (33.3%-91.7% for 3-week T-5224) in the β-aminopropionitrile monofumarate-induced AD model.

Conclusions: This cross-sectional compendium of cellular atlases of human ascending aortas during AD progression provides previously unappreciated insights into a transcriptional programme permitting aortic degeneration, highlighting a translational proof of concept for an anti-remodelling intervention as an attractive strategy to manage temporal-specific AD by modulating the tumour necrosis factor-OXPHOS-AP-1 axis.

Keywords
AP-1 transcriptional complex
Aortic dissection
OXPHOS
Phenotypic switch
TNF signalling
scRNA-seq.
Oral Presentation
Interconnections: Cortisol, Microglia and Neuroinflammation in Schizophrenia